Patents by Inventor David Andrew Wyatt
David Andrew Wyatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911917Abstract: A mobile robot including a vision system, the vision system including a camera and an illumination system; the illumination system including a plurality of light sources arranged to provide a level of illumination to an area surrounding the mobile robot; and a control system for controlling the illumination system. The control system adjusts the level of illumination provided by the plurality of light sources based on an image captured by the camera; an exposure time of the camera at the time the image was captured; and robot rotation information.Type: GrantFiled: May 8, 2019Date of Patent: February 27, 2024Assignee: Dyson Technology LimitedInventors: David Finlay Wyatt, David Andrew Richards, Hossein Farid Ghassem Nia, Christopher Andrew Smith
-
Publication number: 20090188491Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: January 16, 2009Publication date: July 30, 2009Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 7498020Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: November 23, 2004Date of Patent: March 3, 2009Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20050207991Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 micrions, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: ApplicationFiled: May 9, 2005Publication date: September 22, 2005Applicant: Glaxo Group LimitedInventors: Rachel Akehurst, Anthony Taylor, David Andrew Wyatt
-
Patent number: 6919069Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: GrantFiled: April 30, 2003Date of Patent: July 19, 2005Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6893628Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that the medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when the formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: March 31, 2003Date of Patent: May 17, 2005Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20040136920Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: December 19, 2003Publication date: July 15, 2004Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20030198600Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: ApplicationFiled: April 30, 2003Publication date: October 23, 2003Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20030165437Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 micrions, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: ApplicationFiled: March 31, 2003Publication date: September 4, 2003Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20030143163Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: March 11, 2003Publication date: July 31, 2003Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20020058011Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: ApplicationFiled: November 8, 2001Publication date: May 16, 2002Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20020031479Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 micrions, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: ApplicationFiled: September 4, 2001Publication date: March 14, 2002Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20020028183Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: June 21, 2001Publication date: March 7, 2002Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6333023Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: GrantFiled: May 1, 2000Date of Patent: December 25, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6306369Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: April 28, 2000Date of Patent: October 23, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6303103Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: June 14, 2000Date of Patent: October 16, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6251368Abstract: A pharmaceutical aerosol formulation which comprises particulate medicament selected from the group consisting of salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant is disclosed. Also disclosed is a method of treating respiratory disorders which comprises administration by inhalation of an effective amount of the, pharmaceutical aerosol formulation which may be contained in a canister.Type: GrantFiled: June 17, 1997Date of Patent: June 26, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
Patent number: 6238647Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: November 2, 1999Date of Patent: May 29, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt -
Patent number: 6221339Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: GrantFiled: May 10, 1999Date of Patent: April 24, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6200549Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: March 9, 1999Date of Patent: March 13, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt